EHA 2019 | How will the sequencing of treatments for DLBCL change in the future?
Ulrich Jäger from the Medical University of Vienna, Vienna, AT, discusses how to decide what treatments to use, and when, for patients with relapsed/refractory (R/R)...
Ulrich Jäger | EHA 2018 | What are the potential causes of aggressive B-cell lymphomas under JAK1/2 inhibition?
Ulrich Jäger on the potential causes of agressive B-cell lymphomas under JAK1/2 inhibition, EHA 2018
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox